

Rolling Out a New Drug: Lessons from Drug-Resistant TB

Adrian Thomas, MD

Johnson & Johnson

Through a dedicated Global Public Health (GPH)

organization, we have established a team of innovators who put the world's most vulnerable at the heart of everything we do—measuring our success in lives impacted.

* Health for Humanity 2020, J&J Internal Analysis, excludes COVID-19 vaccines

Johnson & Johnson

Our mission

Make relevant innovations that save lives, cure patients and prevent disease available—affordable—accessible for the world's most vulnerable & underserved populations

130+

person team across
26 countries



End-to-end

Organization

- Research & Development
- Strategy & External Affairs
- Field-based teams

100+

partners to
deliver impact

120M+

lives impacted
today*



Executive-level leadership



Leverages full capabilities and resources

of Johnson & Johnson

Tuberculosis (TB): Our long-term commitment



Tuberculosis
Our contributions and
ambition in the global effort

1st TB drug with a novel MOA in
nearly 50 years – bedaquiline

>420,000 treatments shipped for
MDR-TB patients in need
in **147 countries**

10 years TB initiative
(2018-2028) to:

- Broaden access to treatment
- Improve detection of undiagnosed cases of TB
- Accelerate R&D to discover next-generation treatments

J&J is working with the Government of South Africa and other partners to comprehensively address the challenge of TB



ACCESS



APPROPRIATE USE



PATIENT FINDING



MEDICAL EDUCATION



DATA GENERATION



AWARENESS CAMPAIGNS

Lessons learned in collaborating at every level



**Working together toward a
TB-Free South Africa**

Global

Catalytic capacity building partnerships

Regulatory innovation to accelerate access

Partnering with Stop TB's Global Drug Facility

South Africa

Strong political will

Engaging private sector, implementation partners

Needs-based approach

Importance of data generation

Sustained commitment

Leveraging local learnings globally